The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and oxaliplatin (L-OHP) chemotherapy: WJOG6510G.
Daisuke Sakai
No relevant relationships to disclose
Hiroya Taniguchi
Honoraria - Bristol-Myers Squibb; Merck; Takeda
Takao Tamura
No relevant relationships to disclose
Naotoshi Sugimoto
No relevant relationships to disclose
Taito Esaki
Honoraria - Merck Serono; Takeda
Hiroyuki Okuda
No relevant relationships to disclose
Toshihiko Matsumoto
No relevant relationships to disclose
Kentaro Yamazaki
Honoraria - Bristol-Myers Squibb; Merck Serono; Takeda; Yakult
Research Funding - Bristol-Myers Squibb
Tadamichi Denda
Honoraria - Bristol-Myers Squibb; Takeda
Kensei Yamaguchi
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Takeda
Takashi Tsuda
No relevant relationships to disclose
Ayumu Hosokawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
Akitaka Makiyama
No relevant relationships to disclose
Kazutoshi Tobimatsu
No relevant relationships to disclose
Fuminori Goda
No relevant relationships to disclose
Satoshi Otsu
No relevant relationships to disclose
Junji Kishimoto
No relevant relationships to disclose
Narikazu Boku
Honoraria - Merck Serono; Takeda
Research Funding - Merck Serono
Shinichiro Nakamura
No relevant relationships to disclose
Ichinosuke Hyodo
Consultant or Advisory Role - Yakult Honsha (U)
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Takeda; Yakult Honsha